T cell receptor–major histocompatibility complex–peptide interface (TCR–MHC–peptide interface)

The T cell receptor–major histocompatibility complex–peptide interface is a molecular binding surface formed when a T cell receptor (TCR) engages a peptide antigen presented by a major histocompatibility complex (MHC) protein on the surface of an antigen-presenting cell[1][3]. This interface is central to adaptive immune recognition, as it determines T cell specificity and activation: - Structural Organization: The TCR recognizes composite structural and chemical features presented by the peptide held in the MHC groove. The variable regions of the TCR directly interact with both the peptide and the MHC molecule, with MHC class I presenting shorter (8–10 residue) peptides and class II presenting longer ones[1][3][6]. - Functional Importance: Upon engagement, this interface triggers a cascade of intracellular signaling via CD3 and associated complexes, leading to T cell activation, clonal expansion, and effector function[5][7]. - Pathology and Therapy: Dysfunction or modulation of this interface is implicated in cancer (as a target for immunotherapy), autoimmunity, and infectious disease. Therapeutic targeting usually exploits alterations in antigen presentation, TCR specificity, or downstream signaling, often through checkpoint blockade or engineered TCRs[7]. - Safety and Biomarkers: Overactivation or maladaptive recognition at this interface can result in immune-related toxicities or insufficient immune responses. Biomarkers include TCR repertoire, immune activation markers, and specific peptide–MHC multimer binding. This interface is not a discrete protein, enzyme, or classic receptor, but rather a transient multi-protein assembly critical for immune system function and a central focus of therapeutic modulation in immunotherapy and vaccine design[3][7][2][6].

Other names

TCR–pMHC interfaceTCR–peptide–MHC complexTCR–antigen–MHC complex

Allosteric modulation, blocking or enhancing TCR recognition, stabilizing/potentiating TCR–MHC–peptide binding, immunomodulation[2][7]